Update on ESTAR tender for rapid AST

Q-linea AB (publ) (OMX: QLINEA) today announces that the Italian Supreme Administrative Court has overturned the previous ruling which was in favour of Q-linea.

Although the ESTAR tender has not yet been formally awarded, Q-linea assesses its chances of winning the tender as low. The tender has a validity of three plus two years and a total value of EUR 1.7 million. It involves nine sites across the region of Tuscany for a total of 3,500 tests per year.

Q-linea continues to have a positive view on the growing Italian market.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea [email protected]

Christer Samuelsson, CFO /IR, Q-linea [email protected]+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner - when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-09-10 19:51 CEST.